Published in Nanomedicine (Lond) on February 14, 2013
Interfacial interactions between natural RBC membranes and synthetic polymeric nanoparticles. Nanoscale (2014) 0.97
Liposome-like Nanostructures for Drug Delivery. J Mater Chem B Mater Biol Med (2013) 0.87
Cell membrane-camouflaged nanoparticles for drug delivery. J Control Release (2015) 0.83
Cell or cell membrane-based drug delivery systems. Theranostics (2015) 0.82
Safe and Immunocompatible Nanocarriers Cloaked in RBC Membranes for Drug Delivery to Treat Solid Tumors. Theranostics (2016) 0.80
An automated multidimensional thin film stretching device for the generation of anisotropic polymeric micro- and nanoparticles. J Biomed Mater Res A (2015) 0.77
Cell membrane-derived nanomaterials for biomedical applications. Biomaterials (2017) 0.76
Biomimetic Acoustically-Responsive Vesicles for Theranostic Applications. Theranostics (2015) 0.75
Gambogic acid-loaded biomimetic nanoparticles in colorectal cancer treatment. Int J Nanomedicine (2017) 0.75
Lipid-based surface engineering of PLGA nanoparticles for drug and gene delivery applications. Biomater Res (2016) 0.75
PLGA/liposome hybrid nanoparticles for short-chain ceramide delivery. Pharm Res (2013) 0.75
Engineered Nanomedicine with Alendronic Acid Corona Improves Targeting to Osteosarcoma. Sci Rep (2016) 0.75
Bio-inspired nanomedicine strategies for artificial blood components. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2017) 0.75
Preparation and Application of Cell Membrane-Camouflaged Nanoparticles for Cancer Therapy. Theranostics (2017) 0.75
Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci U S A (2008) 3.80
UBP43 (USP18) specifically removes ISG15 from conjugated proteins. J Biol Chem (2002) 3.52
Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci U S A (2008) 3.13
UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activity. EMBO J (2006) 2.84
Interferon-inducible ubiquitin E2, Ubc8, is a conjugating enzyme for protein ISGylation. Mol Cell Biol (2004) 2.70
Role of ISG15 protease UBP43 (USP18) in innate immunity to viral infection. Nat Med (2004) 2.59
Enforced viral replication activates adaptive immunity and is essential for the control of a cytopathic virus. Nat Immunol (2011) 2.51
Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett (2007) 2.40
Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc Natl Acad Sci U S A (2011) 2.37
A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis. Nat Med (2006) 2.36
Protein ISGylation modulates the JAK-STAT signaling pathway. Genes Dev (2003) 2.24
High-throughput immunoblotting. Ubiquitiin-like protein ISG15 modifies key regulators of signal transduction. J Biol Chem (2003) 2.24
PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. Biomaterials (2008) 2.21
The interferon-inducible ubiquitin-protein isopeptide ligase (E3) EFP also functions as an ISG15 E3 ligase. J Biol Chem (2005) 2.19
The 8;21 translocation in leukemogenesis. Oncogene (2004) 2.18
Proteomic identification of proteins conjugated to ISG15 in mouse and human cells. Biochem Biophys Res Commun (2005) 2.18
Interferon-stimulated gene 15 and the protein ISGylation system. J Interferon Cytokine Res (2010) 2.14
RUNX1a enhances hematopoietic lineage commitment from human embryonic stem cells and inducible pluripotent stem cells. Blood (2013) 2.00
ISG15 inhibits Nedd4 ubiquitin E3 activity and enhances the innate antiviral response. J Biol Chem (2008) 1.98
Nanoparticle-induced surface reconstruction of phospholipid membranes. Proc Natl Acad Sci U S A (2008) 1.90
Micromachine-enabled capture and isolation of cancer cells in complex media. Angew Chem Int Ed Engl (2011) 1.87
ISG15: the immunological kin of ubiquitin. Semin Cell Dev Biol (2004) 1.87
Ube1L and protein ISGylation are not essential for alpha/beta interferon signaling. Mol Cell Biol (2006) 1.80
Mice lacking the ISG15 E1 enzyme UbE1L demonstrate increased susceptibility to both mouse-adapted and non-mouse-adapted influenza B virus infection. J Virol (2008) 1.73
A biomimetic nanosponge that absorbs pore-forming toxins. Nat Nanotechnol (2013) 1.70
Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem Pharmacol (2012) 1.68
Spatiotemporal controlled delivery of nanoparticles to injured vasculature. Proc Natl Acad Sci U S A (2010) 1.64
Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18/UBP43. Mol Cell Biol (2009) 1.61
Deletion of an AML1-ETO C-terminal NcoR/SMRT-interacting region strongly induces leukemia development. Proc Natl Acad Sci U S A (2004) 1.60
ISG15: a ubiquitin-like enigma. Front Biosci (2005) 1.58
ISG15 modification of the eIF4E cognate 4EHP enhances cap structure-binding activity of 4EHP. Genes Dev (2007) 1.57
Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy. ChemMedChem (2008) 1.57
Regulation of Rap2A by the ubiquitin ligase Nedd4-1 controls neurite development. Neuron (2010) 1.57
Dysregulation of protein modification by ISG15 results in brain cell injury. Genes Dev (2002) 1.57
Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery. Nano Lett (2014) 1.55
Kit-Shp2-Kit signaling acts to maintain a functional hematopoietic stem and progenitor cell pool. Blood (2011) 1.54
SON controls cell-cycle progression by coordinated regulation of RNA splicing. Mol Cell (2011) 1.52
Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma. Nat Rev Drug Discov (2012) 1.52
Nanoparticle-detained toxins for safe and effective vaccination. Nat Nanotechnol (2013) 1.50
Attenuation of AML1-ETO cellular dysregulation correlates with increased leukemogenic potential. Blood (2013) 1.46
Negative effects of GM-CSF signaling in a murine model of t(8;21)-induced leukemia. Blood (2012) 1.42
Enhanced antibacterial potential in UBP43-deficient mice against Salmonella typhimurium infection by up-regulating type I IFN signaling. J Immunol (2005) 1.42
RUNX1 and RUNX1-ETO: roles in hematopoiesis and leukemogenesis. Front Biosci (Landmark Ed) (2012) 1.37
Nanoparticle-assisted combination therapies for effective cancer treatment. Ther Deliv (2010) 1.35
Single-step assembly of homogenous lipid-polymeric and lipid-quantum dot nanoparticles enabled by microfluidic rapid mixing. ACS Nano (2010) 1.35
Immunocompatibility properties of lipid-polymer hybrid nanoparticles with heterogeneous surface functional groups. Biomaterials (2009) 1.35
Antimicrobial property of lauric acid against Propionibacterium acnes: its therapeutic potential for inflammatory acne vulgaris. J Invest Dermatol (2009) 1.35
Different roles for two ubiquitin-like domains of ISG15 in protein modification. J Biol Chem (2008) 1.31
Biofunctionalized targeted nanoparticles for therapeutic applications. Expert Opin Biol Ther (2008) 1.30
ISG15 modification of filamin B negatively regulates the type I interferon-induced JNK signalling pathway. EMBO Rep (2009) 1.30
Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts. Blood (2007) 1.29
ISG15, not just another ubiquitin-like protein. Biochem Biophys Res Commun (2003) 1.29
'Marker-of-self' functionalization of nanoscale particles through a top-down cellular membrane coating approach. Nanoscale (2013) 1.28
Lipopolysaccharide activates the expression of ISG15-specific protease UBP43 via interferon regulatory factor 3. J Biol Chem (2002) 1.25
Sebum free fatty acids enhance the innate immune defense of human sebocytes by upregulating beta-defensin-2 expression. J Invest Dermatol (2009) 1.23
Polymeric nanotherapeutics: clinical development and advances in stealth functionalization strategies. Nanoscale (2013) 1.20
Erythrocyte-inspired delivery systems. Adv Healthc Mater (2012) 1.20
AML1/RUNX1 phosphorylation by cyclin-dependent kinases regulates the degradation of AML1/RUNX1 by the anaphase-promoting complex. Mol Cell Biol (2006) 1.18
MicroRNA programs in normal and aberrant stem and progenitor cells. Genome Res (2011) 1.17
ISG15 modification of ubiquitin E2 Ubc13 disrupts its ability to form thioester bond with ubiquitin. Biochem Biophys Res Commun (2005) 1.17
The p21Waf1 pathway is involved in blocking leukemogenesis by the t(8;21) fusion protein AML1-ETO. Blood (2007) 1.17
AML1/ETO oncoprotein is directed to AML1 binding regions and co-localizes with AML1 and HEB on its targets. PLoS Genet (2008) 1.17
Loss of TLE1 and TLE4 from the del(9q) commonly deleted region in AML cooperates with AML1-ETO to affect myeloid cell proliferation and survival. Blood (2008) 1.16
Complement factor H genotypes impact risk of age-related macular degeneration by interaction with oxidized phospholipids. Proc Natl Acad Sci U S A (2012) 1.16
Disruption of the NHR4 domain structure in AML1-ETO abrogates SON binding and promotes leukemogenesis. Proc Natl Acad Sci U S A (2008) 1.14
Half-antibody functionalized lipid-polymer hybrid nanoparticles for targeted drug delivery to carcinoembryonic antigen presenting pancreatic cancer cells. Mol Pharm (2010) 1.14
Quick synthesis of lipid-polymer hybrid nanoparticles with low polydispersity using a single-step sonication method. Langmuir (2010) 1.14
Polymer--cisplatin conjugate nanoparticles for acid-responsive drug delivery. ACS Nano (2010) 1.12
Polymeric nanoparticles for drug delivery. Methods Mol Biol (2010) 1.12
Artificial micromotors in the mouse's stomach: a step toward in vivo use of synthetic motors. ACS Nano (2015) 1.11
Polymeric nanoparticles with precise ratiometric control over drug loading for combination therapy. Mol Pharm (2011) 1.11
The level of hepatitis B virus replication is not affected by protein ISG15 modification but is reduced by inhibition of UBP43 (USP18) expression. J Immunol (2008) 1.10
The antimicrobial activity of liposomal lauric acids against Propionibacterium acnes. Biomaterials (2009) 1.10
Rapid delivery of drug carriers propelled and navigated by catalytic nanoshuttles. Small (2010) 1.10
Stimuli-responsive liposome fusion mediated by gold nanoparticles. ACS Nano (2010) 1.10
Lipid- and polymer-based nanostructures for cancer theranostics. Theranostics (2012) 1.09
The hematopoietic transcription factor AML1 (RUNX1) is negatively regulated by the cell cycle protein cyclin D3. Mol Cell Biol (2005) 1.08
Therapeutic nanoparticles to combat cancer drug resistance. Curr Drug Metab (2009) 1.08
Bacterial toxin-triggered drug release from gold nanoparticle-stabilized liposomes for the treatment of bacterial infection. J Am Chem Soc (2011) 1.08
Eradication of drug resistant Staphylococcus aureus by liposomal oleic acids. Biomaterials (2010) 1.08
t(8;21)(q22;q22) Fusion proteins preferentially bind to duplicated AML1/RUNX1 DNA-binding sequences to differentially regulate gene expression. Blood (2008) 1.07
PRMT1 interacts with AML1-ETO to promote its transcriptional activation and progenitor cell proliferative potential. Blood (2012) 1.07
Cargo-towing fuel-free magnetic nanoswimmers for targeted drug delivery. Small (2011) 1.06
Combinatorial drug conjugation enables nanoparticle dual-drug delivery. Small (2010) 1.04
Propionibacterium acnes CAMP factor and host acid sphingomyelinase contribute to bacterial virulence: potential targets for inflammatory acne treatment. PLoS One (2011) 1.04
HER-2-targeted nanoparticle-affibody bioconjugates for cancer therapy. ChemMedChem (2008) 1.03
USP18 inhibits NF-κB and NFAT activation during Th17 differentiation by deubiquitinating the TAK1-TAB1 complex. J Exp Med (2013) 1.02
RUNX1/AML1 DNA-binding domain and ETO/MTG8 NHR2-dimerization domain are critical to AML1-ETO9a leukemogenesis. Blood (2008) 1.02
Negative regulation of ISG15 E3 ligase EFP through its autoISGylation. Biochem Biophys Res Commun (2007) 1.02
Ubp43 regulates BCR-ABL leukemogenesis via the type 1 interferon receptor signaling. Blood (2007) 1.02